echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > This antibody can treat new coronavirus mutant infections

    This antibody can treat new coronavirus mutant infections

    • Last Update: 2021-08-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This antibody can treat new coronavirus mutant infections
    This antibody can treat new coronavirus mutant strain infection This antibody can treat new coronavirus mutant strain infection

    The Yan Jinghua team from the Institute of Microbiology, Chinese Academy of Sciences, together with the Wang Chenhui team of Huazhong University of Science and Technology, the Xiao Junyu team of Peking University, the Wang Youchun team of China Food and Drug Control Institute, the Tan Wenjie team of China Center for Disease Control and Prevention, Shanghai Junshi Biomedical Technology Co.
    , Ltd.
    and other institutions, reported for the first time A blocking antibody that targets a variety of coronavirus invasion receptors ACE2; this antibody can effectively prevent and treat the new coronavirus and its mutants from infecting host cells and model animals, and has shown good results in non-human primates Security
    .


    Related research was published online in Nature-Communication on August 17th


    For the first time, a blocking antibody targeting multiple coronavirus invasion receptors ACE2 is reported; this antibody can effectively prevent and treat the infection of host cells and model animals by the new coronavirus and its mutant strains, and is shown in non-human primates Good safety

    The researchers first obtained a blocking monoclonal antibody h11B11 that targets the human ACE2 receptor through rapid screening and humanization of the antibody; the neutralization evaluation of pseudoviruses and true viruses of a variety of coronaviruses confirmed that the antibody h11B11 It has good inhibitory activity against SARS-CoV, new coronavirus and its mutant viruses
    .

    The study found that the combination of the antibody and the new crown therapeutic antibody CB6 developed by the Institute of Microbiology in the early stage can synergistically improve the neutralizing activity
    .


    CB6 monoclonal antibody is an antibody that targets the S protein RBD of the new crown pneumonia virus.


    The researchers conducted further in vivo activity evaluation of the antibody through the hACE2 transgenic mouse infected with the new coronavirus model.
    The results showed that compared with the placebo group, the lungs of the mice in the preventive administration group were basically undetectable; the treatment group was small.
    The virus titer of mouse lungs was significantly reduced; the results of lung pathological section also showed that the pathological changes of the lungs of the mice in the prevention and treatment group were significantly improved
    .

    The researchers used the cynomolgus monkey model to evaluate the preclinical safety of the h11B11 antibody, proving that it has good in vivo safety
    .


    In order to clarify the mechanism of action and binding epitope of the h11B11 antibody, the researchers further analyzed the crystal structure of h11B11 and ACE2; this structure showed that the antibody mainly binds to the α-helix domain at the N-terminus of the ACE2 receptor; the antibody competes through epitopes and space.


    Related paper information: https://doi.


    https://doi.
    org/10.
    1038/s41467-021-25331-x https://doi.
    org/10.
    1038/s41467-021-25331-x
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.